ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

KROS Keros Therapeutics Inc

60,57
3,47 (6,08%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Keros Therapeutics Inc KROS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
3,47 6,08% 60,57 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
57,32 57,32 62,19 60,57 57,10
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
14.3.202413:00GLOBEKeros Therapeutics Announces U.S. FDA Fast Track Designation..
06.3.202414:01EDGAR2Form 8-K - Current report
05.3.202414:02EDGAR2Form 8-K - Current report
05.3.202414:01EDGAR2Form 8-K - Current report
05.3.202414:00GLOBEKeros Therapeutics to Present at Leerink Partners 2024..
28.2.202422:02EDGAR2Form 8-K - Current report
28.2.202422:01GLOBEKeros Therapeutics Reports Recent Business Highlights and..
23.2.202423:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202402:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202402:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.1.202414:00GLOBEKeros Therapeutics To Present at Pulmonary Vascular Research..
09.1.202414:01EDGAR2Form 8-K - Current report
09.1.202414:00GLOBEKeros Therapeutics Announces Closing of Upsized Public..
08.1.202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:04EDGAR2Form 8-K - Current report
04.1.202422:04EDGAR2Form 144 - Report of proposed sale of securities
04.1.202422:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04.1.202403:29GLOBEKeros Therapeutics Announces Pricing of Upsized Public..
03.1.202422:05GLOBEKeros Therapeutics Announces Proposed Public Offering of..
03.1.202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03.1.202414:04EDGAR2Form 8-K - Current report
11.12.202312:02EDGAR2Form 8-K - Current report
11.12.202312:00GLOBEKeros Therapeutics Presents Clinical Data from its KER-050..
07.11.202314:01EDGAR2Form 8-K - Current report
07.11.202314:00GLOBEKeros Therapeutics to Present at Upcoming Healthcare..
06.11.202314:11EDGAR2Form 8-K - Current report
06.11.202314:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06.11.202314:01EDGAR2Form 8-K - Current report
06.11.202314:00GLOBEKeros Therapeutics Reports Recent Business Highlights and..
02.11.202314:00GLOBEKeros Therapeutics to Present at the 65th American Society..
04.10.202314:01EDGAR2Form 8-K - Current report
04.10.202314:00GLOBEKeros Therapeutics Presents Preclinical Data from its..
05.9.202314:02EDGAR2Form 8-K - Current report
05.9.202314:00GLOBEKeros Therapeutics to Present at Upcoming Healthcare..
07.8.202322:02EDGAR2Form 8-K - Current report
07.8.202314:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.8.202314:00EDGAR2Form 8-K - Current report
07.8.202314:00GLOBEKeros Therapeutics Reports Recent Business Highlights and..
27.7.202322:01GLOBECorrected: Keros Therapeutics to Host Conference Call and..
24.7.202314:01EDGAR2Form 8-K - Current report
24.7.202314:00GLOBEKeros Therapeutics to Host Conference Call and Webcast to..
12.6.202314:00GLOBEKeros Therapeutics Announces Update to Participation at the..
09.6.202312:00GLOBEKeros Therapeutics Presents Clinical Trial and Preclinical..
07.6.202314:00GLOBEKeros Therapeutics to Present at Goldman Sach’s 44th Annual..
22.5.202315:00GLOBEKeros Therapeutics Presents Preclinical and Clinical Data..
11.5.202322:01GLOBEKeros Therapeutics to Present at the 28th Annual Congress of..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock